Navigation Links
First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System
Date:5/22/2013

n onto a Nitinol self-expanding stent. The high-quality bioprosthesis is durable, ensuring long-term aortic valve function.
  • JenaValve's unique "3-feeler element" allows the clinician to accurately position the prosthesis in the anatomically correct position during implantation thus ensuring a precise sub-coronary alignment within the patient's native valve.
  • JenaClip™ anchoring and clipping mechanism allows the patient's native valve leaflets to be clipped to the valve enabling the JenaValve to be firmly anchored in the correct anatomical position and provide active fixation and resistance to migration.
  • The JenaValve implantation is conducted on the beating heart. Hemodynamic flow is maintained without cardiac arrest and rapid pacing is not required during the procedure. The low profile of the stent prosthesis ensures open flow to the coronaries after the implantation. The JenaValve is available in three sizes, 23mm, 25mm and 27mm, covering aortic valve annuli from 21mm to 27mm.
  • JenaValve is retrievable and repositionable thereby contributing to a successful procedure and confidence of the clinician.
  • About JenaValve Technology

    JenaValve Technology, Inc., domiciled in Delaware, USA with operations in Munich, Germany, develops, manufactures and markets aortic valve systems to treat patients suffering from aortic valve disease. The company's products are CE marked and its transapical aortic valve system is currently marketed in Europe with over 400 implantations to date. JenaValve is backed by world-class U.S. and European investors: Atlas Venture, Edmond de Rothschild Investment Partners, NeoMed Management, VI Partners, Sunstone Capital and GIMV. Additional information is available at www.jenavalve.com  

    European Contact: JenaValve Technology GmbH, Guerickestr. 25, 80805 Muni
    '/>"/>

    SOURCE JenaValve Technology, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Thoratec Schedules First Quarter Conference Call, Webcast
    3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
    4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
    7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
    8. Insmed to Host 2012 First Quarter Earnings Conference Call
    9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
    10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
    11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
    (Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
    (Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
    Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
    ... Group -, BRISBANE, Calif., May 28 ... clinical trials program through the,initiation of an additional ... The trial will assess BSI-201, the first ADP-ribose ... for the treatment,of uterine carcinosarcoma or malignant mixed ...
    ... C and LymphoStat-B(R) for lupus on track for ... potential launch in 2010 -,- ABthrax(TM) for inhalation anthrax on track to begin delivery fall ... ... - GSK to advance darapladib to Phase 3 for atherosclerosis -, ROCKVILLE, ...
    Cached Medicine Technology:BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
    (Date:4/24/2014)... scientists a better understanding of drug interactions, which are ... , When two or more medications are taken at ... effectiveness of the other. Similarly, one drug may ... are a major cause of illness and hospitalization. ... scope of drug studies in humans. Limits come ...
    (Date:4/24/2014)... (April 24, 2014) - Contact lenses coated with an antimicrobial ... infections, reports a study in Optometry and Vision ... of Optometry . The journal is published by ... Kluwer Health . , Studies in animals and now humans ... antimicrobial peptide melimine, according to the new research by Debarun ...
    (Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
    (Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
    (Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
    Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
    ... behavior is linked to risk-taking, too, study finds, ... thrill-seeking behavior that makes people love skydiving, mountain-climbing ... an area of the brain that has been ... and Purdue University researchers studied volunteers who were ...
    ... LANSING, Mich. Women are 30 percent less likely ... can limit brain damage after a stroke, according to ... were presented Feb. 19 in San Diego at the ... and American Stroke Association. , Tissue plasminogen activator, or ...
    ... 19 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY; BOVESPA: USIM3,USIM5, USIM6; Latibex: ... USIMINAS Fourth Quarter 2008 Results Conference Call., ... the opening, ... 2009 at 10:00 AM EST in English, ...
    ... (Nasdaq: MYL ) today announced that its Vice ... NASDAQ Stock Market opening on Friday, Feb. 20 from 9:15 ... to celebrate the company,s switch from The New York Stock ... Dec. 29, 2008. The company is listed on the NASDAQ ...
    ... pancreatitis remains a disease with an unpredictable clinical ... the elevated intraabdominal pressure (IAP) after onset of ... is increasingly recognized as an important risk factor ... disease. However, It is still not clear whether ...
    ... Executives at Sage, an industry-,leading provider of ... records (EHR - http://tinyurl.com/ah9dgb ) system ... federally qualified,health centers, today joined with forward-looking ... the signing of the American,Reinvestment and Recovery ...
    Cached Medicine News:Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast 2Health News:Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell 2Health News:Should intra-abdominal pressure measurement be a routine for all pancreatitis patients? 2Health News:Electronic Health Records (EHR) 'Leap Forward' Thanks to American Reinvestment and Recovery Act 2Health News:Electronic Health Records (EHR) 'Leap Forward' Thanks to American Reinvestment and Recovery Act 3
    Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
    Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
    Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 6mm from tip. Tip ang...
    ... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
    Medicine Products: